Funding for this trial has been provided in full or in part by Cystic Fibrosis Foundation Therapeutics, Inc.
Number of Participants Being Recruited:
Single / Multi-Center:
STUDY BACKGROUND INFORMATION:
Cystic Fibrosis Related Diabetes (CFRD) is associated with worse nutritional status, greater decline in pulmonary function, and increased mortality. This study aims to understand the impact of the new CF agent, ivacaftor, upon blood sugar and insulin. Knowledge gained from this study can lead to better understanding of the use of these new CFTR medications in interrupting progressive insulin deficiency and development of CFRD. Specimins of blood and urine will be taken throughout the study along with pulmonary function testing.
>= 6 Years
P. aeruginosa status:
B. cepacia status:
Other Primary Eligibility Requirements:
Study subjects must have at least 1 copy of G551D mutation.
Note: Detailed eligibility criteria information may be available on clinicaltrials.gov. If a specific
trial listing for this trial is available, a link to the specific clinicaltrials.gov listing will be present in the "More Information" section below.
The sites listed below are currently recruiting subjects. Please note that this list generally lists either the pediatric or adult program but not both even though both programs may be recruiting subjects. Also, this list does not include sites that may be participating in the study but are not yet open for recruitment. If you are interested in this study please contact your center for more information.
Children's Hospital of Philadelphia University of Pennsylvania (Pediatric), Philadelphia, PA, 19104
Kubrak, Christina Phone: (267) 426-5135 Email: email@example.com